HC Wainwright Issues Positive Outlook for MIRM Earnings

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) – HC Wainwright increased their Q3 2026 earnings per share (EPS) estimates for shares of Mirum Pharmaceuticals in a report issued on Monday, September 28th. HC Wainwright analyst S. Ramakanth now expects that the company will post earnings of $0.07 per share for the quarter, up from their previous estimate of ($0.31). HC Wainwright has a “Buy” rating and a $195.00 price target on the stock. The consensus estimate for Mirum Pharmaceuticals’ current full-year earnings is ($1.31) per share. HC Wainwright also issued estimates for Mirum Pharmaceuticals’ Q4 2026 earnings at ($0.11) EPS, Q3 2027 earnings at $0.35 EPS, FY2028 earnings at $5.38 EPS, FY2029 earnings at $7.21 EPS and FY2030 earnings at $10.03 EPS.

Several other equities analysts also recently weighed in on MIRM. TD Cowen decreased their price target on shares of Mirum Pharmaceuticals from $145.00 to $140.00 and set a “buy” rating on the stock in a research note on Thursday, August 6th. Royal Bank Of Canada dropped their price objective on shares of Mirum Pharmaceuticals from $148.00 to $135.00 and set an “outperform” rating for the company in a research note on Thursday, August 6th. Citigroup reiterated a “buy” rating and issued a $160.00 price objective (up from $145.00) on shares of Mirum Pharmaceuticals in a report on Monday. Robert W. Baird raised their target price on shares of Mirum Pharmaceuticals from $123.00 to $130.00 and gave the stock an “outperform” rating in a research note on Tuesday. Finally, UBS Group set a $137.00 target price on Mirum Pharmaceuticals in a report on Thursday, August 27th. One analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, Mirum Pharmaceuticals presently has a consensus rating of “Moderate Buy” and a consensus price target of $142.56.

Mirum Pharmaceuticals Price Performance

Mirum Pharmaceuticals stock opened at $83.92 on Wednesday. Mirum Pharmaceuticals has a 52-week low of $63.23 and a 52-week high of $130.00. The firm has a market capitalization of $5.45 billion, a price-to-earnings ratio of -5.77 and a beta of 0.61. The company has a fifty day simple moving average of $98.55 and a 200-day simple moving average of $101.37. The company has a quick ratio of 2.74, a current ratio of 2.86 and a debt-to-equity ratio of 1.28.

Mirum Pharmaceuticals (NASDAQ:MIRM) last issued its quarterly earnings results on Wednesday, August 5th. The company reported ($1.06) EPS for the quarter, missing the consensus estimate of ($0.74) by ($0.32). Mirum Pharmaceuticals had a negative return on equity of 36.28% and a negative net margin of 139.18%.The firm had revenue of $176.24 million for the quarter, compared to analysts’ expectations of $166.33 million. During the same quarter in the previous year, the firm posted ($0.12) earnings per share. The firm’s revenue for the quarter was up 37.9% compared to the same quarter last year.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in MIRM. Contravisory Investment Management Inc. increased its holdings in Mirum Pharmaceuticals by 2.3% in the second quarter. Contravisory Investment Management Inc. now owns 4,604 shares of the company’s stock valued at $539,000 after buying an additional 103 shares during the last quarter. ABS Investment Management LLC bought a new position in Mirum Pharmaceuticals during the 2nd quarter worth approximately $245,847,000. Faithward Advisors LLC lifted its holdings in Mirum Pharmaceuticals by 0.5% during the 1st quarter. Faithward Advisors LLC now owns 27,467 shares of the company’s stock worth $2,537,000 after buying an additional 126 shares during the last quarter. Integrated Wealth Concepts LLC acquired a new position in shares of Mirum Pharmaceuticals in the 2nd quarter worth approximately $27,000. Finally, Quantbot Technologies LP acquired a new position in shares of Mirum Pharmaceuticals in the 2nd quarter worth approximately $44,000.

Insiders Place Their Bets

In other Mirum Pharmaceuticals news, CEO Christopher Peetz sold 30,000 shares of the business’s stock in a transaction dated Tuesday, September 1st. The shares were sold at an average price of $98.68, for a total value of $2,960,400.00. Following the transaction, the chief executive officer directly owned 194,440 shares in the company, valued at $19,187,339.20. The trade was a 13.37% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Eric Bjerkholt sold 6,001 shares of the stock in a transaction that occurred on Tuesday, August 11th. The shares were sold at an average price of $99.90, for a total transaction of $599,499.90. Following the completion of the sale, the chief financial officer directly owned 36,355 shares of the company’s stock, valued at approximately $3,631,864.50. This trade represents a 14.17% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 123,499 shares of company stock valued at $12,854,484 over the last ninety days. Company insiders own 8.32% of the company’s stock.

Key Mirum Pharmaceuticals News

Here are the key news stories impacting Mirum Pharmaceuticals this week:

• Positive Sentiment: The FDA approved Mirum’s Atebrioz, a potentially important catalyst that expands the company’s commercial portfolio and could improve future revenue and earnings prospects. Mirum wins FDA approval for Atebrioz
• Positive Sentiment: HC Wainwright maintained a Buy rating and a $195 price target, well above the current trading level. The firm raised its EPS forecasts for Q3 2026 to $0.07 from a prior loss estimate of $0.31, FY2028 to $5.38 from $3.96, FY2029 to $7.21 from $5.71, and FY2030 to $10.03 from $7.12. These revisions signal stronger expected profitability as Mirum’s products mature. Mirum Pharmaceuticals stock price expected to rise
• Neutral Sentiment: A head-to-head comparison of Mirum and Sarepta Therapeutics provides broader investment context but does not represent a direct change to Mirum’s earnings, operations, or outlook. Mirum Pharmaceuticals and Sarepta Therapeutics head-to-head survey
• Negative Sentiment: HC Wainwright trimmed its Q3 2027 EPS forecast to $0.35 from $0.40, indicating some near-term uncertainty despite the firm’s substantially higher long-term earnings estimates. Mirum remains expected to post a full-year loss of $1.31 per share in the current year.

Mirum Pharmaceuticals Company Profile

Mirum Pharmaceuticals, Inc is a biopharmaceutical company focused on developing and commercializing medicines for rare diseases of the liver and gastrointestinal system. The company’s work centers on conditions involving impaired bile acid transport and cholestasis, which can cause serious liver damage and debilitating symptoms such as itching.

Mirum’s primary commercial product is Livmarli (maralixibat), an oral ileal bile acid transporter inhibitor. In the United States, Livmarli is approved to treat cholestatic pruritus associated with Alagille syndrome and progressive familial intrahepatic cholestasis in eligible pediatric patients.